Manufacturer record

Yaxon Biocare Pvt.Ltd: regulatory record

Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories

1 batch manufactured by Yaxon Biocare Pvt.Ltd (Haryana) was declared Not of Standard Quality in April 2024. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.

Most recent flagged batch: YEX-463, Clindamycin and Adapalene Gel (CLON- A Gel) (exp Dec 2025). RDTL Chandigarh (CDSCO lab) found it not of standard quality: Assay of Clindamycin Phosphate calculated as Clindamycin. Listed in the April 2024 alert.

Records by type

1 record linked to Yaxon Biocare Pvt.Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.

0Banned or prohibited
0Recalled or suspended
1Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source

CDSCO drug alerts: Not of Standard Quality and spurious drugs

CDSCO · CDSCO monthly NSQ alerts, Apr 2024 to Apr 2024

View original document

Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.

1
NSQ batches since 2024
1
Products affected
Assay
Most common failure
Apr 2024
Latest alert

Flagged batches per year

2024 · 1

All flagged batches

Product Batch Reason declared NSQ Tested by Alert
Clindamycin and Adapalene Gel (CLON- A Gel) Batch YEX-463Mfg Jan 2024 · Exp Dec 2025 Assay of Clindamycin Phosphate calculated as ClindamycinAssay RDTL ChandigarhCDSCO lab Apr 2024

Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.